Combining the novel anti-CD47 antibody magrolimab with azacitidine in patients with TP53-mutant AML

Bookmark and Share
Published: 26 Jun 2020
Views: 891
Dr Naval Daver - MD Anderson Cancer Center, Houston, USA

Dr Naval Daver speaks to ecancer in an online interview for the virtual EHA 2020 meeting.

He describes the background, study design and results of this phase 1B trial, which investigated the combination magrolimab and azacitidine in patients with untreated acute myeloid leukaemia (AML) and a TP53 mutation.

Dr Daver concludes that this novel treatment combination is well tolerated and effective in patients who are unfit for chemotherapy, and follow up studies are planned to investigate this further. 

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.